Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Valerie Lecouturier"'
Autor:
Catherine Berry, Vincent Pavot, Natalie G. Anosova, Michael Kishko, Lu Li, Tim Tibbitts, Alice Raillard, Sylviane Gautheron, Sheila Cummings, Dinesh S. Bangari, Swagata Kar, Caroline Atyeo, Yixiang Deng, Galit Alter, Cindy Gutzeit, Marguerite Koutsoukos, Roman M. Chicz, Valerie Lecouturier
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-16 (2023)
Abstract Background Since the beginning of the COVID-19 pandemic, several variants of concern (VOC) have emerged for which there is evidence of an increase in transmissibility, more severe disease, and/or reduced vaccine effectiveness. Effective COVI
Externí odkaz:
https://doaj.org/article/7ddec5d298994b9fb951ab9ada5f2108
Autor:
Yixiang Deng, Caroline Atyeo, Dansu Yuan, Taras M. Chicz, Timothy Tibbitts, Matthew Gorman, Sabian Taylor, Valerie Lecouturier, Douglas A. Lauffenburger, Roman M. Chicz, Galit Alter, Ryan P. McNamara
Publikováno v:
Cell Reports, Vol 42, Iss 11, Pp 113292- (2023)
Summary: The reduced effectiveness of COVID-19 vaccines due to the emergence of variants of concern (VOCs) necessitated the use of vaccine boosters to bolster protection against disease. However, it remains unclear how boosting expands protective bre
Externí odkaz:
https://doaj.org/article/3ca3d9bbd3e34f9c984c4517eebda1d6
Autor:
Vincent Pavot, Catherine Berry, Michael Kishko, Natalie G. Anosova, Lu Li, Tim Tibbitts, Dean Huang, Alice Raillard, Sylviane Gautheron, Cindy Gutzeit, Marguerite Koutsoukos, Roman M. Chicz, Valerie Lecouturier
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)
Waning protective efficacy of mRNA-based booster vaccinations has been observed against newly emerging SARS-CoV-2 variants of concern. In this work, Pavot et al. formulate a monovalent Beta vaccine and demonstrate durable cross-neutralising antibody
Externí odkaz:
https://doaj.org/article/82bb567df3234c4eb6b85d8731df0e1a
Autor:
Simon Collett, Linda Earnest, Julio Carrera Montoya, Melissa A. Edeling, Ashley Yap, Chinn Yi Wong, Dale Christiansen, Jason Roberts, Jamie Mumford, Valerie Lecouturier, Vincent Pavot, Sergio Marco, Joon Keit Loi, Cameron Simmons, Shivali A. Gulab, Jason M. Mackenzie, Aaron Elbourne, Paul A. Ramsland, Garth Cameron, Dhiraj Hans, Dale I. Godfrey, Joseph Torresi
Publikováno v:
Frontiers in Microbiology, Vol 14 (2023)
The development of virus-like particle (VLP) based vaccines for human papillomavirus, hepatitis B and hepatitis E viruses represented a breakthrough in vaccine development. However, for dengue and COVID-19, technical complications, such as an incompl
Externí odkaz:
https://doaj.org/article/db5da8de105e44ddb37fe0edcbcb6989
Autor:
Vincent Pavot, Catherine Berry, Michael Kishko, Natalie G. Anosova, Dean Huang, Tim Tibbitts, Alice Raillard, Sylviane Gautheron, Cindy Gutzeit, Marguerite Koutsoukos, Roman M. Chicz, Valerie Lecouturier
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Emerging SARS-CoV-2 variants of concern (VOCs) raise questions on vaccine effectiveness. Here, the authors show that an adjuvanted protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization of VOC, including omicron, in non-human p
Externí odkaz:
https://doaj.org/article/c8ccb39de4d2489d998cfdfb67a40d60
Autor:
Nicholas Glanville, Gary R McLean, Bruno Guy, Valerie Lecouturier, Catherine Berry, Yves Girerd, Christophe Gregoire, Ross P Walton, Rebecca M Pearson, Tatiana Kebadze, Nicolas Burdin, Nathan W Bartlett, Jeffrey W Almond, Sebastian L Johnston
Publikováno v:
PLoS Pathogens, Vol 9, Iss 9, p e1003669 (2013)
Human rhinovirus (RV) infections are the principle cause of common colds and precipitate asthma and COPD exacerbations. There is currently no RV vaccine, largely due to the existence of ∼150 strains. We aimed to define highly conserved areas of the
Externí odkaz:
https://doaj.org/article/07717b4341ab44fc8f7b80ae6c35376c
Autor:
Vincent Pavot, Catherine Berry, Michael Kishko, Natalie Anosova, Lu Li, Tim Tibbitts, Alice Raillard, Sylviane Gautheron, Cindy Gutzeit, Marguerite Koutsoukos, Roman Chicz, Valerie Lecouturier
Rapid spread of the SARS-CoV-2 Omicron subvariants despite the implementation of booster vaccination has raised questions about the durability of protection conferred by current vaccines. Vaccines that can induce broader and more durable immune respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1df1f5123c090593527357733f928058
https://doi.org/10.21203/rs.3.rs-2372287/v1
https://doi.org/10.21203/rs.3.rs-2372287/v1
Autor:
Catherine Berry, Vincent Pavot, Natalie Anosova, Michael Kishko, Dean Huang, Tim Tibbitts, Alice Raillard, Sylviane Gautheron, Sheila Cummings, Dinesh Bangari, Swagata Kar, Caroline Atyeo, Yixiang Deng, Galit Alter, Cindy Gutzeit, Marguerite Koutsoukos, Roman Chicz, Valerie Lecouturier
Background Since the beginning of the COVID-19 pandemic, several variants of concern (VOC) have emerged for which there is evidence of an increase in transmissibility, more severe disease, and/or reduced vaccine effectiveness. Effective COVID-19 vacc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16e9a2ccc11a8cddb29e530d7503f5ad
https://doi.org/10.21203/rs.3.rs-1928234/v1
https://doi.org/10.21203/rs.3.rs-1928234/v1
Autor:
Tim Tibbitts, Cindy Gutzeit, Natalie G. Anosova, Vincent Pavot, Sylviane Gautheron, Valerie Lecouturier, Roman Chicz, Catherine C. Berry, Dean Huang, Michael G. Kishko, Alice Raillard, Marguerite Koutsoukos
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that partly evade neutralizing antibodies has raised concerns of reduced vaccine effectiveness and increased infection. We previously demonstrated in preclinical m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::849f0ef5d859aae7a1975cabfda8d15a
https://doi.org/10.21203/rs.3.rs-871537/v1
https://doi.org/10.21203/rs.3.rs-871537/v1
Autor:
Anthony L. Cook, Hanne Leth Andersen, John-Paul Todd, Sophie Ruiz, Katharine Floyd, Tongqing Zhou, Evan Lamb, Shayne F. Andrew, Britta Flach, Sally Shin, Timothy S. Johnston, Catherine C. Berry, Sarah O’Connell, Nancy J. Sullivan, Joseph R. Francica, Stephanie Fischinger, Alida Tylor, Dapeng Li, Kathryn E. Foulds, Daniel C. Douek, Robert A. Seder, Alex Lee Zhu, Ian N. Moore, Rachel L. Davis, Roman Chicz, Mark G. Lewis, Courtney Tucker, Alex Van Ry, Elizabeth McCarthy, Barney S. Graham, Marguerite Koutsoukos, Robbert van der Most, I.-Ting Teng, Amy T. Noe, Cindy Gutzeit, Matthew Gagne, Mitzi M. Donaldson, Alan Dodson, Tong-Ming Fu, Saule T. Nurmukhambetova, Laurent Pessaint, Venkata Viswanadh Edara, Adrian B. McDermott, Renee van de Wetering, Kizzmekia S. Corbett, Peter D. Kwong, Danilo Casimiro, Timothy Tibbitts, Barbara J. Flynn, Seyhan Boyoglu-Barnum, Valerie Lecouturier, Matthew J. Gorman, Anne P. Werner, Dillon R. Flebbe, Mehul S. Suthar, Mario Roederer, Lilin Lai, Caroline Atyeo, Barton F. Haynes, Galit Alter
Publikováno v:
Science Translational Medicine. 13
Adjuvanted soluble protein vaccines have been used extensively in humans for protection against various viral infections based on their robust induction of antibody responses. Here, soluble prefusion-stabilized spike protein trimers (preS dTM) from s